ONCAlert | Upfront Therapy for mRCC

Lymphomas VIEW MORE >>

Patients with refractory large B-cell lymphoma who were treated with Axi-cel had a 3-year overall survival rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.